Key points † The vasoconstrictor endothelin-1 (ET-1) is involved in changes to the microcirculation in sepsis. † The effect of ET-1 is mediated by two receptors, but their individual role is unclear. † This study found that both the endothelin Aand the endothelin B receptor needs to be blocked in order to improve microcirculatory blood flow in the intestinal mucosa in porcine endotoxaemia.
1
Conventional therapy is guided by systemic haemodynamic parameters, but in septic patients with similar systemic haemodynamics, alterations in the microcirculation have been correlated to patient outcome. 2 The use of vasodilators to open up the microcirculation has a possible role as a new therapeutic strategy in sepsis and septic shock. Damage to the intestinal mucosa with increased permeability and translocation of the mucosal barrier has been proposed to work as a trigger of systemic inflammation contributing to the development of multiple organ failure. 3 4 Microcirculation in the splanchnic organs is impaired in sepsis, 5 6 and therapies aimed at restoring microcirculatory blood flow and preventing splanchnic organ dysfunction could potentially be of major importance in the treatment of sepsis. Plasma levels of the potent vasoconstrictor endothelin-1 (ET-1) are elevated in sepsis, 7 and ET-1 has been implicated in the pathogenesis of the microcirculatory dysfunction seen in septic shock. 8 ET-1 effects are mediated by two subtypes of G-protein-coupled endothelin receptors, the endothelin A-(ETAR) and endothelin B-(ETBR) receptors. The ETAR is primarily expressed on vascular smooth muscle and mediates vasoconstriction. The actions of the ETBR are more complex and dependent on the location of the receptor. ETBR located on vascular smooth muscle cells mediates vasoconstriction, but ETBR located on endothelial cells induces vasodilation through release of NO and prostacyclin. 9 10 The ETBR is also involved in the clearance of ET-1, 11 12 and blocking the ETBR raises plasma levels of ET-1 under normal conditions 11 and in endotoxaemia. 13 We have previously shown that the mixed endothelin receptor antagonist tezosentan improves microvascular blood flow in the ileal mucosa in a porcine model of endotoxaemia. 14 However, in our previous study, tezosentan also had major beneficial effects on cardiac function and central haemodynamics, making it hard to evaluate whether the positive effects of tezosentan on intestinal microvascular blood flow were due to direct effects on the microvasculature or mainly appeared secondary to an improvement in central circulation and metabolic parameters. Also, the effects of tezosentan on the distribution of microcirculatory flow within the intestinal wall have not yet been investigated, and we could not rule out that the positive effects on ileal mucosal blood flow occurred at the expense of microcirculatory flow in the muscularis, rendering this layer ischaemic.
The interplay between the ET-1 receptors in regulating regional blood flow and splanchnic microcirculation is complex and not fully understood. The vasodilating properties of the ETBR have been suggested to have a protective effect on microcirculatory blood flow, possibly making selective ETAR antagonism a more beneficial alternative than mixed endothelin receptor antagonism. Furthermore, selective ETAR antagonism would leave the ETBR-mediated clearance of ET-1 intact. However, data on the role of the individual ET-1 receptors in mediating splanchnic microcirculatory failure are sparse and conflicting, and studies using large animal models are lacking.
In this study, we wanted to investigate to what extent the mixed endothelin receptor antagonist tezosentan and the selective ETAR antagonist TBC3711 can act as splanchnic vasodilators on a microcirculatory level in endotoxaemia. Furthermore, in order to better understand the factors behind the ET-1-induced splanchnic microcirculatory failure, we aimed to investigate the importance of the different endothelin receptors in modulating splanchnic regional blood flow and microvascular blood flow in endotoxaemia.
Methods
An expanded Methods section is available in the Supplementary material.
The experimental protocol was approved by the ethics committee for experiments in animals, Stockholm, Sweden. Eighteen female pigs weighing 28-37 kg were fasted for 24 h before surgery with free access to water. Anaesthesia and surgical preparation have been described in detail previously.
14 Briefly after premedication with ketamine hydro- 2 ). Plasma levels of ET-1-like immunoreactivity (ET-1 LI) in arterial and mesenteric vein blood were analysed with radioimmunoassay using a specific antiserum (E1), raised against porcine ET-1 in rabbits, as described earlier in detail by Hemsen. 15 
Experimental protocol
After surgical preparation, all animals were given an infusion of saline with glucose 25 mg ml 21 
Results

Effects of endotoxaemia (T0 -T120)
In spite of an increase in heart rate (HR), endotoxin administration resulted in a decrease in cardiac index (CI) (P¼0.02; Table 1 ), but MAP and Sv O 2 were preserved during the first 120 min (Table 1) . MPAP increased as expected (P,0.001; Table 1 ), resulting in a decrease in PO 2 (P,0.001; Table 2 ) and an increase in PCO 2 (P,0.001; Table 2 ). SMA FI increased (P¼0.001; Fig. 1 ), but in spite of this, microcirculatory blood flow in the ileum deteriorated ( Fig. 1 ) and both PCO 2muc -art (P,0.001; Fig. 1 ) and lact mes (P,0.001; Table 2 ) increased. PV FI (P,0.001; Fig. 2 ) and hepatic microcirculatory blood flow (MCQ hep, P¼0.01; Fig. 2 ) were reduced in response to endotoxaemia.
Haemoglobin (Hb) increased indicating haemoconcentration (P,0.001; Table 2 ). Base excess (BE) decreased (P,0.001; Table 2 ), and together with the raised PCO 2 (P,0.001; Table 2 ), this resulted in a decrease in pH (Table 2 ). Body temperature increased as a result of endotoxin administration (P,0.001; Table 2 ). As expected, both systemic and mesenteric vein ET-1 LI levels increased (P,0.001 for both; Table 2 ). T0-T120 was not different between the groups for any of the parameters above.
Systemic and pulmonary effects of treatment (T120 -T300)
Tezosentan administration preserved CI, but in both the endotoxin-treated control group and TBC3711 group, CI deteriorated from T120 to T300 (Table 1) . No difference in HR was found between the groups (P¼0.07; Table 1 ). Tezosentan also partly prevented the decrease in Sv O 2 seen in endotoxin-treated controls, but compared with the TBC3711 group, this effect did not reach statistical significance (P¼0.07; Table 1 ). Both treatments lowered MAP compared with endotoxin-treated controls (Table 1 ). TBC3711 and tezosentan prevented the pulmonary hypertension seen in the endotoxin-treated control group (Table 1) , and PO 2 improved in treatment groups compared with endotoxin-treated controls (Table 2 ). Both treatments also attenuated the increase in PCO 2 seen in the endotoxin-treated control group (Table 2) , resulting in a significantly higher pH at T300 in treatment groups (Table 2) . BE decreased in all groups without any intergroup differences (P¼0.47; Table 2 ).
Hb increased in the endotoxin-treated control group compared with treatment groups, indicating greater haemoconcentration in endotoxin-treated controls (Table 2) . Body temperature increased throughout the experiment without any differences between the groups (P¼0.44; Table 2 ). As expected, tezosentan induced an increase in plasma levels of ET-1 LI, but no difference was found between endotoxin-treated controls and the TBC3711 group (P¼0.73; Table 2 ). Splanchnic effects of treatment (T120 -300)
SMA FI deteriorated in all groups without any intergroup differences (P¼0.53; Fig. 1 ). Tezosentan preserved microcirculatory blood flow in the ileal mucosa (MCQ muc ) compared with the TBC3711 group and endotoxin-treated controls ( Fig. 1 ), but no differences in microcirculatory blood flow in the muscularis (MCQ musc ) were found between the groups (P¼0.32; Fig. 1 ). PCO 2muc -art improved in the tezosentan group compared with other groups (Fig. 1) . Tezosentan also attenuated the increase in lact mes seen in the endotoxintreated control group, but compared with the TBC3711 group, this effect did not reach statistical significance (P¼0.05; Table 2 ). Mesenteric vein levels of ET-1 LI increased significantly more in the tezosentan group, but no difference between the endotoxin-treated control group and the TBC3711 group was found (P¼0.95; Table 2 ). Tezosentan preserved PV FI but failed to significantly improve MCQ hep compared with the TBC3711 group and endotoxin-treated controls (P¼0.77; Fig. 2 ).
Discussion
Microcirculatory dysfunction is considered to be an important part of the pathogenesis of sepsis and septic shock, 18 but the factors behind this microcirculatory failure are still incompletely known. ET-1 is a powerful splanchnic vasoconstrictor, and has been implicated in the pathogenesis of splanchnic microcirculatory failure in several conditions, including sepsis 8 and endotoxaemia. 14 In this study, we used the highly selective ETAR antagonist TBC3711 and the mixed endothelin receptor antagonist tezosentan to investigate the role of the different endothelin receptors in controlling regional splanchnic blood flow and splanchnic microvascular blood flow in porcine endotoxaemia. TBC3711 did not improve splanchnic regional blood flow or splanchnic microvascular blood flow, but tezosentan improved MCQ muc without any significant increase in superior mesenteric artery flow, indicating a direct positive effect of tezosentan on the microcirculation. The fact that dual endothelin receptor antagonism was necessary to improve MCQ muc implies a Endothelin and microcirculation in endotoxaemia role for the ETBR in mediating the microcirculatory failure seen in the ileal mucosa. We have previously shown that mixed endothelin receptor antagonism with tezosentan improves microcirculatory blood flow in the ileal mucosa in endotoxaemia.
14 However, the importance of the different endothelin receptors in mediating the deterioration of microcirculatory blood flow in the intestinal mucosa is unclear. Selective ETAR antagonism has theoretical advantages in preserving the ETBR-mediated vasodilation and clearance of ET-1, and ETAR antagonism has previously been shown to attenuate ET-1-induced vasoconstriction in the intestinal microcirculation 19 under normal conditions. The data on effects of selective ETAR antagonism on intestinal microcirculatory blood flow in endotoxaemia or sepsis are to date very sparse. In a rat model of endotoxaemia, Miura and colleagues 20 showed that the ETAR antagonist BQ-123 improved intestinal microvascular blood flow, implying that the ETAR was mainly responsible for the ET-1-induced vasoconstriction in the intestine. In contrast to those results, our findings show that in porcine endotoxaemia, tezosentan, but not TBC3711, improved microcirculatory blood flow in the ileal mucosa. This indicates that when the ETAR is blocked, the ETBR mediates a powerful vasoconstriction in the ileal microcirculation, and hence selective ETAR antagonism is not enough to counteract the ET-1-induced vasoconstriction in the ileal mucosa. The interplay between the ETAR and ETBR is complex, and previous studies have indicated that a cross-talk seems to exist between the receptors under normal conditions. In a recent study investigating ET-1-mediated effects on renal blood flow in rats, 21 ETBR-mediated actions in the renal circulation varied as a function of ETAR activity. When ETBR and ETAR were stimulated simultaneously, the ETBR induced vasodilation to compensate for the vasoconstrictive properties of the ETAR. In contrast, when the ETBR was selectively activated without concomitant ETAR stimulation, the response seemed to be predominantly vasoconstriction.
A possible explanation to the lack of positive microcirculatory effects of selective ETAR antagonism in our study is that a similar interaction between the endothelin receptors is effective in the microcirculation of the ileal mucosa in endotoxaemia. Alternatively, the inflammatory response elicited by endotoxaemia could affect the different endothelin receptor subgroups and their signalling pathways, changing the response elicited by activation of the ETBR to a predominant vasoconstriction in the microvasculature. The relationship between regional blood flow and microcirculatory blood flow in the ileum in endotoxaemia is not fully understood. We did not find any difference in SMA FI between the groups, indicating that ET-1 is not of major importance in regulating blood flow in the superior mesenteric artery. A major finding in this study is that treatment with tezosentan improved ileal mucosal microcirculatory blood flow in the absence of an improved SMA FI . This is, to our knowledge, the first report showing that the positive effect of mixed endothelin receptor antagonism on microcirculatory blood flow in the ileal mucosa is not only secondary to an increase in regional blood flow, but is also caused by a direct effect on the microcirculation. Also, although MAP was lower in the tezosentan group, microcirculatory blood flow in the ileal mucosa was still improved compared with controls, showing that microcirculatory changes were not related to changes in MAP in this model. In line with our previous results, 14 PCO 2muc -art improved in the tezosentan group, indicating that the increase in microcirculatory blood flow improved the relationship between oxygen supply and demand in the ileal mucosa. In further support of this, the tezosentan group also had a lower lact mes compared with the endotoxin-treated control group, and a strong tendency (P¼0.05) towards a lower lact mes than the TBC3711 group.
In endotoxaemia, the initial decrease in microcirculatory blood flow is larger in the intestinal muscularis than in the mucosa, redistributing microcirculatory flow from the muscularis to the mucosa. 22 23 The mechanism behind this redistribution of flow is not known. In this model, neither tezosentan nor TBC3711 significantly improved microcirculatory blood flow in the muscularis. The fact that ET-1 is more important as a vasoconstrictor in the mucosa than in the muscularis indicates that ET-1 is not the main factor behind the redistribution of microcirculatory blood flow to the mucosa. Our data also show that the positive effects on microcirculatory blood flow in the mucosa seen with tezosentan did not occur at the expense of the microcirculation in the muscularis layer.
Mixed endothelin receptor antagonism with tezosentan has been shown to ameliorate hepatic injury in sepsis and endotoxaemia, 24 but neither tezosentan nor the mixed ET receptor antagonist bosentan improved hepatic microcirculatory blood flow in porcine models of endotoxaemia 14 or cecal ligation and puncture (CLP). 8 Selective ETAR antagonism has been shown to have positive effects on the hepatic microcirculation in models of ischaemia/reperfusion 25 and acute liver failure, 26 indicating an advantage of maintaining ETBR activation in those settings. Previous data on the effects of selective ETAR antagonism on liver injury in endotoxaemia are conflicting. 27 28 Studies on the effects of selective ETAR antagonism on hepatic microcirculation in sepsis or endotoxaemia are very sparse, but in a rat model of endotoxaemia, Nishida and colleagues 29 found that the ETAR antagonist BQ-485 had detrimental effects on hepatic microcirculatory blood flow. In our model, TBC3711 neither improved nor worsened hepatic microcirculatory blood flow compared with endotoxin-treated controls. Although there was a tendency towards an improved hepatic microvascular blood flow with tezosentan, we were not able to show any statistically significant improvement in hepatic microvascular blood flow. This could partly be explained by the limited number of animals used. Still, this is the third study using porcine models of endotoxaemia or CLP failing to demonstrate a significant improvement of hepatic microcirculatory blood flow with mixed ET receptor antagonism, and together, these results imply that in porcine endotoxaemia ET-1 is not the main determinant of microcirculatory blood flow in the liver. However, laser Doppler flowmetry does not allow us to measure heterogeneity of flow in the microcirculation, and possibly ET-1 could influence the distribution of microcirculatory blood flow in a way that we were not able to detect with laser Doppler flowmetry. Also, we measured microcirculatory blood flow on the surface of the liver, and ET-1 could be of greater importance for the microcirculation in deeper layers. The amount of fluid infused was set to 20 ml kg 21 h 21 , and this rate was kept constant throughout the experiment to prevent any differences in volume loading between the groups from interfering with the results. In spite of this fluid strategy, the initial central haemodynamic response in all groups before treatment at T120 was a preserved MAP but a reduction in CI. After T120, the control group and the TBC3711 group continued to develop a hypodynamic shock, while CI was preserved in the tezosentan group. Cardiac dysfunction with myocardial depression is a common feature of septic shock. 30 The improved CI in the tezosentan group indicates beneficial cardiac effects of mixed endothelin receptor antagonism compared with selective ETAR antagonism, and this is in line with previous studies. 31 32 TBC3711 has a very high selectivity for the ETAR over the ETBR, 441 000:1, 16 making it a useful tool when investigating the effects of the different endothelin receptors. Compared with endotoxin-treated controls, TBC3711 and tezosentan were both effective in lowering MAP and MPAP. This is well in line with previous studies using selective ETAR antagonists, 31 and shows that TBC3711 effectively blocked the ETAR. As expected when also blocking the ETBR, arterial and mesenteric vein ET-1 LI levels were significantly higher in the tezosentan group compared with endotoxin-treated controls and the TBC3711 group. The fact that ET-1 LI levels in endotoxintreated controls and in the TBC3711 group were virtually identical supports the absence of ETBR blocking effects of TBC3711. During recent years, therapy aimed at restoring the microcirculation has been proposed as a new concept in sepsis, and our findings support this therapeutic strategy. However, results from animal models of endotoxaemia are not directly applicable to the clinical situation of bacterial sepsis in humans, and this should be kept in mind when interpreting the results.
To further investigate the effects of the different ET receptors on regional splanchnic blood flow and microvascular blood flow, it would have been of interest to also use a selective ETBR antagonist. Unfortunately, this was not possible, since selective ETBR antagonism has proven lethal in previous studies using the same model. 13 Blocking the ETBR increases circulating ET-1 which will then act upon the ETAR, thereby inducing an overwhelming vasoconstriction. Changes in haematocrit can to some extent influence the values obtained by laser Doppler flowmetry. In our study, the endotoxin-treated control group showed an increase in Hb concentration compared with the treatment groups. In theory, this could possibly have affected the laser Doppler measurements, but the effect produced by the level of difference in haematocrit seen in our study is likely of a limited magnitude, and it is not probable that this influenced our results in any major way.
In conclusion, mixed endothelin receptor antagonism with tezosentan improves microcirculatory blood flow in the ileal mucosa independent of SMA FI , demonstrating a direct positive effect of tezosentan on the microcirculation in endotoxaemia. Selective ETAR antagonism with TBC3711 failed to improve microvascular blood flow in the ileal mucosa, indicating a role for the ETBR in mediating the endotoxininduced microcirculatory failure seen in the ileal mucosa in this model. In porcine endotoxaemia, ET-1 seems to be of limited importance in modulating microvascular blood flow in the liver and ileal muscularis, as neither tezosentan nor TBC3711 improved microcirculatory blood flow in these vascular beds.
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